Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III safety and immunogenicity study of TAK-816 Hib vaccine in healthy Japanese infants
jRCT2080222404Phase 3
- Sponsor
- Takeda
- Start
- Feb 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of VaxemHIB in Haemophilus influenzae type b disease (Hib), sponsored by Takeda.
02
Drugs
VaxemHIB
03
Conditions
Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on jRCT2080222404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222404.